October 24, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America
 

Tokyo, July 26, 2013 (JCN) - Takara Bio Inc. announced today that it has entered into a distribution agreement with Nippon Zenyaku Kogyo Co., Ltd ("ZENOAQ"), and will start to market ZENOAQ's CELLBANKER series of cell cryopreservation media exclusively in Japan from August 1. The products will be also supplied non-exclusively in Europe and North America.

ZENOAQ's CELLBANKER series, which was launched in 1992, has gained a dominant share of the market for cell cryopreservation medium in Japan because of its significant advantages when compared with other conventional freezing media.

The products provide consistent high cell viability while maintaining cell pluripotency after a freeze-thaw cycle. No programmed freezer or liquid nitrogen tank is required, and it is a ready-to-use formulation with a simple protocol that minimizes contamination risk from particles, mycoplasma, and other contaminants.

In the near future, the research market for freezing stem cells such as human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) is expected to grow substantially for applications in the regenerative medicine field.

By adding ZENOAQ's CELLBANKER products, which are fully complementary to Takara Bio's molecular biology products such as PCR-related enzymes, Takara Bio will continue to offer a broad range of innovative new products that support development of biotechnology research.

In addition to the Japanese market, Takara Bio has also established a strong sales and marketing presence in the American or European markets. Takara Bio will focus on sale of ZENOAQ's products in these markets through its local subsidiaries; Clontech Laboratories Inc. in the U.S. and Takara Bio Europe SAS in France.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin reagent, which is a world-standard in gene therapy protocols.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Takara Bio  News  
  Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy  (May 12, 2014)
  Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy  (Apr 10, 2014)
  Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America  (July 26, 2013)
  Takara Bio launches Nippi's iMatrix-511 Worldwide  (July 12, 2013)
  Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production  (June 24, 2013)
  Takara Bio Licenses Mushroom Production Technology to Sun Toward Tech  (June 13, 2013)
  Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial  (Jan 7, 2013)
  Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA  (Mar 23, 2012)
  Takara Bio and Tianjin Medical University in Gene Therapy Project  (Aug 3, 2011)
  Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma  (Dec 18, 2008)



 Recent  Biotech News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)